Discusson
We were successful in obtaining background data on five of the six cases reported to the Committee on Safety of Medicine. We found that in one of these the patient had stopped taking viloxazine before the attack which led to her death and it is therefore extremely unlikely that the drug could have been a contributing factor.
Withdrawal from benzodiazepines was thought to be the most likely cause of the convulsions in patients 1 and 4. Benzodiazepine withdrawal was considered as a possible explanation in the first of these4 but at the time the case was reported convulsive seizures due to withdrawal from therapeutic doses of benzodiazepines were regarded as extremely rare. 24 Withdrawal from benzodiazepines as a cause of convulsions has since become more widely recognised and in our opinion it is a cause that is frequently overlooked. Depressive illnesses are often accompanied by symptoms of anxiety or present as anxiety states and benzodiazepines are prescribed for their treatment. When it becomes apparent that the patient is suffering from a depressive illness the benzodiazepines are discontinued and antidepressants substituted. Benzodiazepinewithdrawal symptoms occur and the antidepressants are erroneously incriminated.
The most likely cause of the convulsion in patient 2 was hepatic encephalopathy although if viloxazine has epileptogenic properties it is possible that abnormally high plasma levels due to hepatic failure could have caused or contributed to the convulsion. In the case of patient 3, maprotiline 25 mg tds had been stopped three days before the convulsion. It is not known how long the patient had been receiving Edwards, Glen-Bott this drug but with a mean plasma half-life that ranges from 27 to 108 hours25 26 it is highly probable that maprotiline was still present in the circulation. More cases of convulsions occurring during treatment with this drug have been reported to the Committee on Safety of Medicine than with any other antidepressant marketed in the United Kingdom. It is therefore just as likely that maprotiline caused the attack as viloxazine.
Insufficient information was obtained on patient 5, but in so far as the seizure occurred after the first two doses of viloxazine this drug must be considered as a possible (though not probable) cause of the attack.
We also had insufficient information on the Japanese cases. Uraemia must be considered as a more likely cause of the attack than viloxazine in the first (elderly) patient while amitriptyline may also be implicated. The second patient had a history of convulsions preceding the use of viloxazine which at worst could be regarded as a contributory (rather than causative) factor.
Rating the relationship between viloxazine and convulsions on a five-point scale ranging from "almost certainly" due to the drug to "almost certainly not" due to the drug27 we believe that in only two out of the seven cases referred to could viloxazine be regarded as a "possible" cause of the convulsions. As already stated we had insufficient background information on one of these and in the other maprotiline could be an equally likely cause.
It is noteworthy that in all but one of the seven cases cited the patient was a woman. This probably reflects the higher prevalence of depression in women28 and the fact that antidepressants are prescribed more often for them than for men. 2930 The discussion has focused on viloxazine as a possible cause of convulsions when given in therapeutic doses. It cannot be concluded that this 
